|Mr. Peter Jonathan Butterfield||CEO & Exec. Director||612.03k||N/A||1976|
|Mr. Andrew Timothy Franklin||CFO & Exec. Director||349.23k||N/A||1966|
|Mr. Stephen Kidner||Chief Scientific Affairs & Operations Officer||N/A||N/A||N/A|
|Mr. Daniel Thomas||Chief Corp. Devel. Officer||N/A||N/A||N/A|
|Ms. Janice Timberlake||Chief People & Infrastructure Officer||N/A||N/A||N/A|
|Mr. Steve Lobb||Head of Hydromol||N/A||N/A||N/A|
|Mr. David Hope||Head of Secondary Care||N/A||N/A||N/A|
|Mr. Alex Duggan||Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Rajiv Ghidiyal||Head of APAC, EMEA & Americas||N/A||N/A||N/A|
|Mr. Karim Husny||Head of International||N/A||N/A||N/A|
Alliance Pharma plc operates as a pharmaceutical company in the United Kingdom, Republic of Ireland, Mainland Europe, the United States, and internationally. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It owns or licenses the rights to approximately 80 pharmaceutical and consumer healthcare products. The company also offers medical devices, food supplements, and cosmetics. In addition, the company provides its products under the Kelo-Cote, Nizoral, MacuShield, Vamousse, Flamma Franchise, Aloclair, Hydromol, Forceval, Optiflo, Oxyplastine, Ashton & Parsons, and Ametop brand names. Alliance Pharma plc was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Alliance Pharma plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.